Across TCGA pan-cancer cohorts, RAD54L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAD54L data layer compared with 29 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RAD54L Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated RAD54L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, STAD, and PRAD are the cancer types where RAD54L Mutation most reproducibly stratifies survival.